[CLSTR]
API
< Back to situations

Monitor this situation.

[SITUATION] · [QUIET] · [HEALTH]

2 clusters · 3 sources · 19 days · First seen · Last updated

Multiple myeloma Phase 3 clinical trial developments

Overview

Recent clinical developments in multiple myeloma treatment have seen positive Phase 3 trial results from major pharmaceutical companies.

Bristol Myers Squibb reported that its Zenbexus regimen, used in combination with daratumumab and dexamethasone, met the second primary endpoint of progression-free survival in the EXCALIBER-RRMM trial. In patients with relapsed or refractory multiple myeloma, the regimen demonstrated a median progression-free survival of 42 months, compared to 20 months for the control group.

Pfizer announced that its treatment, Elrexfio, met the primary endpoint in the MagnetisMM-32 Phase 3 trial. The study, which involved 523 adults across 26 countries, focused on patients who had previously received anti-CD38 therapy and lenalidomide. Results indicated an estimated 18-month progression-free survival rate of 68%, with Elrexfio reducing the risk of disease progression or death compared to control regimens.

Entities

American Society of Hematology · iberdomide · Pfizer · Bristol Myers Squibb

Timeline

  1. [HEALTH] 3 sources
    Pfizer reports positive Phase 3 trial results for Elrexfio in myeloma

    Pfizer’s Elrexfio met its primary endpoint in a Phase 3 trial for multiple myeloma, showing improved progression-free survival in patients treated earlier than current indications allow.

  2. [HEALTH] 2 sources
    Bristol Myers Squibb reports positive Phase 3 results for Zenbexus in myeloma trial

    Bristol Myers Squibb’s Phase 3 EXCALIBER-RRMM trial shows Zenbexus combination therapy reduces the risk of disease progression or death by 51% in relapsed or refractory multiple myeloma patients.

Sources

ad-hoc-news.de · econoTimes.com · mugglehead.com